Esperion Therapeutics/ESPR

$1.84

-1.6%
-
1D1W1MYTD1YMAX

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

Ticker

ESPR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sheldon Koenig

Employees

240

Headquarters

Vero beach, United States

ESPR Metrics

BasicAdvanced
$348.5M
Market cap
-
P/E ratio
-$2.11
EPS
0.91
Beta
-
Dividend rate
$348.5M
0.90582
$3.40
$0.70
6.69M
1.287
0.867
-2.85%
-92.23%
-203.94%
2.996
54.14%
40.41%
-20.04%

What the Analysts think about ESPR

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
302.72% upside
High $16.00
Low $2.90
$1.84
Current price
$7.41
Average price target

ESPR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-174.84% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$32.2M
-5.01%
Net income
$-56.3M
36.65%
Profit margin
-174.84%
43.87%

ESPR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.63%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.79
-$0.46
-$0.37
-$0.50
-
Expected
-$0.65
-$0.61
-$0.43
-$0.48
$0.05
Surprise
21.1%
-24.75%
-14.4%
3.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Esperion Therapeutics stock?

Esperion Therapeutics (ESPR) has a market cap of $354.18M as of April 21, 2024.

What is the P/E ratio for Esperion Therapeutics stock?

The price to earnings (P/E) ratio for Esperion Therapeutics (ESPR) stock is 0 as of April 21, 2024.

Does Esperion Therapeutics stock pay dividends?

No, Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders as of April 21, 2024.

When is the next Esperion Therapeutics dividend payment date?

Esperion Therapeutics (ESPR) stock does not pay dividends to its shareholders.

What is the beta indicator for Esperion Therapeutics?

Esperion Therapeutics (ESPR) has a beta rating of 0.9. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Esperion Therapeutics stock price target?

The target price for Esperion Therapeutics (ESPR) stock is $7.41, which is 280% above the current price of $1.95. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Esperion Therapeutics stock

Buy or sell Esperion Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing